{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:21:27Z","timestamp":1782508887649,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1714-9","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T09:44:32Z","timestamp":1537177472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-826X","authenticated-orcid":false,"given":"Tristan","family":"Pascart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Grandjean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoist","family":"Capon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Namane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ducoulombier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Motte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vandecandelaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Luraschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Godart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Houvenagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laur\u00e8ne","family":"Norberciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Budzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,17]]},"reference":[{"key":"1714_CR1","doi-asserted-by":"publisher","unstructured":"Pascart T, Liote F. Gout: state of the art after a decade of developments. Rheumatology (Oxford). 2018. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/key002\n                    \n                  .","DOI":"10.1093\/rheumatology\/key002"},{"key":"1714_CR2","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/acr.22855","volume":"68","author":"A Abhishek","year":"2016","unstructured":"Abhishek A, Valdes AM, Zhang W, Doherty M. Association of serum uric acid and disease duration with frequent gout attacks: a case-control study. Arthritis Care Res (Hoboken). 2016;68:1573\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1714_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/rheumatology\/keq363","volume":"50","author":"D Rothenbacher","year":"2011","unstructured":"Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodriguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50:973\u201381.","journal-title":"Rheumatology (Oxford)"},{"key":"1714_CR4","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64:1447\u201361.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1714_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, et al. 2016 Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1714_CR6","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/rheumatology\/kex150","volume":"56","author":"Michelle Hui","year":"2017","unstructured":"Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald TM, et al. The British Society for Rheumatology Guideline for the management of gout. Rheumatology (Oxford). 2017. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kex150\n                    \n                  .","journal-title":"Rheumatology"},{"key":"1714_CR7","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450\u201361.","journal-title":"N Engl J Med"},{"key":"1714_CR8","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/art.40233","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, Thienel U, Gunawardhana L. Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69:2386\u201395.","journal-title":"Arthritis Rheumatol."},{"key":"1714_CR9","first-page":"2429","volume":"31","author":"GC Borstad","year":"2004","unstructured":"Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429\u201332.","journal-title":"J Rheumatol"},{"key":"1714_CR10","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/art.39684","volume":"68","author":"J Poiley","year":"2016","unstructured":"Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, Boudes PF, Arhalofenate Flare Study I. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. 2016;68:2027\u201334.","journal-title":"Arthritis Rheumatol"},{"key":"1714_CR11","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/rheumatology\/keu157","volume":"53","author":"A Latourte","year":"2014","unstructured":"Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014;53:1920\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"1714_CR12","doi-asserted-by":"publisher","unstructured":"Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andres M, et al. Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout. Arthritis Care Res (Hoboken). 2018. \n                    https:\/\/doi.org\/10.1002\/acr.23607\n                    \n                  .","DOI":"10.1002\/acr.23607"},{"key":"1714_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/15257770802136032","volume":"27","author":"MA Becker","year":"2008","unstructured":"Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27:585\u201391.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1714_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13075-017-1381-2","volume":"19","author":"T Pascart","year":"2017","unstructured":"Pascart T, Grandjean A, Norberciak L, Ducoulombier V, Motte M, Luraschi H, Vandecandelaere M, Godart C, Houvenagel E, Namane N, et al. Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study. Arthritis Res Ther. 2017;19:171.","journal-title":"Arthritis Res Ther."},{"key":"1714_CR15","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1136\/ard.2008.099713","volume":"68","author":"HK Choi","year":"2009","unstructured":"Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G, Nicolaou S. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis. 2009;68:1609\u201312.","journal-title":"Ann Rheum Dis"},{"key":"1714_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jbspin.2014.03.011","volume":"82","author":"S Ottaviani","year":"2015","unstructured":"Ottaviani S, Gill G, Aubrun A, Palazzo E, Meyer O, Dieude P. Ultrasound in gout: a useful tool for following urate-lowering therapy. Joint Bone Spine. 2015;82:42\u20134.","journal-title":"Joint Bone Spine."},{"key":"1714_CR17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, et al. 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789\u201398.","journal-title":"Ann Rheum Dis"},{"key":"1714_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/annrheumdis-2017-212046","volume":"77","author":"N Dalbeth","year":"2018","unstructured":"Dalbeth N, Nicolaou S, Baumgartner S, Hu J, Fung M, Choi HK. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol. Ann Rheum Dis. 2018;77:364\u201370.","journal-title":"Ann Rheum Dis"},{"key":"1714_CR19","doi-asserted-by":"publisher","first-page":"i27","DOI":"10.1093\/rheumatology\/kex445","volume":"57","author":"N Dalbeth","year":"2018","unstructured":"Dalbeth N, Doyle AJ. Imaging tools to measure treatment response in gout. Rheumatology (Oxford). 2018;57:i27\u201334.","journal-title":"Rheumatology (Oxford)"},{"key":"1714_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13075-018-1602-3","volume":"20","author":"T Pascart","year":"2018","unstructured":"Pascart T, Capon B, Grandjean A, Legrand J, Namane N, Ducoulombier V, Motte M, Vandecandelaere M, Luraschi H, Godart C, et al. The lack of association between the burden of monosodium urate crystals assessed with dual-energy computed tomography or ultrasonography with cardiovascular risk in the commonly high-risk gout patient. Arthritis Res Ther. 2018;20:97.","journal-title":"Arthritis Res Ther"},{"key":"1714_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3899\/jrheum.170911","volume":"45","author":"LK Stamp","year":"2018","unstructured":"Stamp LK, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, Christensen R. Variability in the reporting of serum urate and flares in gout clinical trials: need for minimum reporting requirements. J Rheumatol. 2018;45:419\u201324.","journal-title":"J Rheumatol"},{"key":"1714_CR22","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1007\/s00330-016-4237-2","volume":"26","author":"T Finkenstaedt","year":"2016","unstructured":"Finkenstaedt T, Manoliou A, Toniolo M, Higashigaito K, Andreisek G, Guggenberger R, Michel B, Alkadhi H. Gouty arthritis: the diagnostic and therapeutic impact of dual-energy CT. Eur Radiol. 2016;26:3989\u201399.","journal-title":"Eur Radiol"},{"key":"1714_CR23","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/rheumatology\/kev112","volume":"54","author":"M Gutierrez","year":"2015","unstructured":"Gutierrez M, Schmidt WA, Thiele RG, Keen HI, Kaeley GS, Naredo E, Iagnocco A, Bruyn GA, Balint PV, Filippucci E, et al. International consensus for ultrasound lesions in gout: results of Delphi process and web-reliability exercise. Rheumatology (Oxford). 2015;54:1797\u2013805.","journal-title":"Rheumatology (Oxford)"},{"key":"1714_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jbspin.2011.12.006","volume":"79","author":"F Liote","year":"2012","unstructured":"Liote F, Lancrenon S, Lanz S, Guggenbuhl P, Lambert C, Saraux A, Chiarelli P, Delva C, Aubert JP, Ea HK. GOSPEL: prospective survey of gout in France. Part I: design and patient characteristics (n = 1003). Joint Bone Spine. 2012;79:464\u201370.","journal-title":"Joint Bone Spine"},{"key":"1714_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","volume":"73","author":"F Perez-Ruiz","year":"2014","unstructured":"Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73:177\u201382.","journal-title":"Ann Rheum Dis"},{"key":"1714_CR26","doi-asserted-by":"publisher","unstructured":"Stamp L, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M, Christensen R. Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regression analysis. Semin Arthritis Rheum. 2018. \n                    https:\/\/doi.org\/10.1016\/j.semarthrit.2018.02.009\n                    \n                  .","DOI":"10.1016\/j.semarthrit.2018.02.009"},{"key":"1714_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.7326\/M16-0570","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Harris RP, Forciea MA. Clinical Guidelines Committee of the American College of Physicians: Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:58\u201368.","journal-title":"Ann Intern Med"},{"key":"1714_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrrheum.2017.126","volume":"13","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Bardin T, Doherty M, Liote F, Richette P, Saag KG, So AK, Stamp LK, Choi HK, Terkeltaub R. Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat Rev Rheumatol. 2017;13:561\u20138.","journal-title":"Nat Rev Rheumatol"},{"key":"1714_CR29","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jama.2018.0547","volume":"319","author":"BM Kuehn","year":"2018","unstructured":"Kuehn BM. Chronic disease approaches needed to curb gout's growing burden. JAMA. 2018;319:1307\u20139.","journal-title":"JAMA"},{"key":"1714_CR30","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540\u20138.","journal-title":"Arthritis Rheum"},{"key":"1714_CR31","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63.","journal-title":"Arthritis Res Ther."},{"key":"1714_CR32","doi-asserted-by":"publisher","first-page":"e000075","DOI":"10.1136\/rmdopen-2015-000075","volume":"1","author":"EG Araujo","year":"2015","unstructured":"Araujo EG, Bayat S, Petsch C, Englbrecht M, Faustini F, Kleyer A, Hueber AJ, Cavallaro A, Lell M, Dalbeth N, et al. Tophus resolution with pegloticase: a prospective dual-energy CT study. RMD Open. 2015;1:e000075.","journal-title":"RMD Open"},{"key":"1714_CR33","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/rheumatology\/kex442","volume":"57","author":"F Perez-Ruiz","year":"2018","unstructured":"Perez-Ruiz F, Moreno-Lledo A, Urionaguena I, Dickson AJ. Treat to target in gout. Rheumatology (Oxford). 2018;57:i20\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"1714_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1617","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, White WB, Lipsky PE, Horowitz Z, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011;306:711\u201320.","journal-title":"JAMA"},{"key":"1714_CR35","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/ar4318","volume":"15","author":"HS Baraf","year":"2013","unstructured":"Baraf HS, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, Yood RA. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013;15:R137.","journal-title":"Arthritis Res Ther."},{"key":"1714_CR36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.40381","volume":"70","author":"AL Gaffo","year":"2018","unstructured":"Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, Chen YH, Lin CT, Bourke S, Louthrenoo W, et al. Brief Report: Validation of a definition of flare in patients with established gout. Arthritis Rheumatol. 2018;70:462\u20137.","journal-title":"Arthritis Rheumatol."},{"key":"1714_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12891-016-0943-9","volume":"17","author":"AN Baer","year":"2016","unstructured":"Baer AN, Kurano T, Thakur UJ, Thawait GK, Fuld MK, Maynard JW, McAdams-DeMarco M, Fishman EK, Carrino JA. Dual-energy computed tomography has limited sensitivity for non-tophaceous gout: a comparison study with tophaceous gout. BMC Musculoskelet Disord. 2016;17:91.","journal-title":"BMC Musculoskelet Disord"},{"key":"1714_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2214\/AJR.14.13901","volume":"206","author":"TM Coupal","year":"2016","unstructured":"Coupal TM, Mallinson PI, Gershony SL, McLaughlin PD, Munk PL, Nicolaou S, Ouellette HA. Getting the most from your dual-energy scanner: recognizing, reducing, and eliminating artifacts. AJR Am J Roentgenol. 2016;206:119\u201328.","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"1714_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/annrheumdis-2017-211343","volume":"77","author":"Ashika Chhana","year":"2017","unstructured":"Chhana A, Doyle A, Sevao A, Amirapu S, Riordan P, Dray M, McGlashan S, Cornish J, Dalbeth N. Advanced imaging assessment of gout: comparison of dual-energy CT and MRI with anatomical pathology. Ann Rheum Dis. 2017. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2017-211343\n                    \n                  .","journal-title":"Annals of the Rheumatic Diseases"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1714-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T19:18:09Z","timestamp":1568661489000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1714-9"}},"subtitle":["MSU burden and risk of gout flare"],"short-title":[],"issued":{"date-parts":[[2018,9,17]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1714"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1714-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,17]]},"assertion":[{"value":"23 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for the study was received from the Institutional Medical Ethics Review Board of the Lille Catholic Hospitals (reference number 2016-04-06). All patients provided informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"210"}}